TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04803435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine Consultation
Description: Brief telemedicine consultation, blindedto subsequent face-to-face evaluation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face Consultation
Description: Direct face-to-face evaluation (without telemedicine consultation before).
Study: NCT04717583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment
Description: After randomization, one side of the face will be treated with IPL using the M22™ Universal IPL device, once every 4 weeks for 3 consecutive times.~Starting from Week 12 (the time point of the primary endpoint), the control side of face will also be treated by IPL if the IPL-treated side shows satisfactory improvement of erythema or telangiectasia by IPL treatment. If the patient was unsatisfied with the improvement in the IPL-treated side at Week 12 visit, no IPL treatment will be given to either side of the face any more.
Study: NCT06516731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pH Balanced Cleanser
Description: Participants will use the pH Balanced Cleanser daily during showers. The cleanser should be applied to the vulva with clean hands, gently worked into a lather, and rinsed clean. Participants will complete baseline and weekly questionnaires and vaginal pH tests over an 8-week period to evaluate the effects on vulvar and vaginal health, including odor and pH levels, and assess the tolerability of the product.
Study: NCT06243159

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JY231
Description: Infusion of JY231 Injection by dose of 1-10×10\^6 TU/kg、 1-5×10\^7 TU/kg、5-10 ×10\^7 TU/kg Administration method: intravenous infusion、Splenic artery infusion、Lymph node infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion (PI evaluation is required)
Study: NCT05364489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with Oxaliplatin and TAS-102
Description: Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).~Oxaliplatin: 85 mg/m2, repeated every 2 weeks, by intravenous infusion (ivgtt). TAS-102: 35 mg/m2 (maximum single dose 80 mg), orally, twice a day, on days 1 to 5, repeated every 2 weeks.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug .
Study: NCT05682469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR cognitive training
Description: All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~All participants will receive one immersive leisure-based VR cognitive training for 40 minutes. VR cognitive training receives four gardening activities.~The cognitive elements including attention, working memory, processing speed, and executive function incorporated training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cognitive training
Description: All participants will receive trainings for 60 minutes per day, two days per week for 16 sessions.~The control group is performing traditional cognitive training program.
Study: NCT05721261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Peripheral Nerve Stimulation System
Description: Single use medical device. Therapy consists of single, 1 hour dose of electrical stimulation delivered proximal to injury site.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Temporary Peripheral Nerve Stimulation System
Description: Single use medical device. Sham treatment consists of single, 1 hour dose of sham stimulation.
Study: NCT04267237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1680 mg will be administered by intravenous (IV) infusion on Day 1 of Cycles 1-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7198457
Description: RO7198457 will be administered by IV infusion at protocol-defined intervals for 12 cycles.
Study: NCT06476080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided erector spine block
Description: Ultrasound guided thoracic erector spinae block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior block
Description: Ultrasound guided serratus anterior block
Study: NCT05595395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Dose Form
Description: In this intervention arm, fluid substitution is primarily done via enteral administration. The used substance for enteral fluid administered is going to be tap water. Intravenous fluid of choice is going to be Elomel isoton.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Infusion
Description: In this intervention arm, fluid substitution is primarily done via intravenous administration. The used substance for intravenous fluid administered is going to be Elomel isoton.
Study: NCT06465290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamed-based active movement training with wearable ankle robot
Description: Active movement training through movement games with robotic assistance
Study: NCT03899597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
Study: NCT06465290

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive movement with limited wearable ankle robot
Description: Passive movement in the joint middle range of motion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active movement training with limited wearable ankle robot
Description: Active movement training without robotic assistance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle torque and motion measurement with limited wearable ankle robot
Description: Ankle torque and motion measurement with no real-time feedback
Study: NCT06719375

Intervention type: DEVICE
Intervention: Gait Analysis Using IMU Sensor
Description: Inertial Measurement Unit (IMU) sensor-based 3D gait analysis to assess spasticity and gait impairment. This intervention aims to provide quantitative data on gait parameters in DCM patients before and after surgery.
Study: NCT06040450

Intervention type: OTHER
Intervention: Questionnaire survey
Description: On outdoor sports practice activity, barriers to practice, impacts on well-being.

Intervention type: OTHER
Intervention: Questionnaire survey
Description: On outdoor sports practice activity, barriers to practice, impacts on well-being.
Study: NCT06716424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iGlarLixi (insulin glargine/lixisenatide)
Description: iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously
Study: NCT04743895

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless Steel Wire Cerclage
Description: Wire cerclage used to close sternum after cardiothoracic surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless Steel Wire Cerclage
Description: Wire cerclage used to close sternum after cardiothoracic surgery.
Study: NCT05018819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05655572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Theraoy
Description: After initial baseline assessment patients allocated in AOT group will undergo treatment protocol of 6 weeks having 4 stages of duration 1.5 weeks each performed 3 days per week. . Assessment will be perform at baseline after 2, 4 and 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Training
Description: after baseline assessment participants including in this group will perform the tasks for 6 weeks (3 days per week) s and after that again assessment will be made for examining the improvements.Assessment will be perform at baseline after 2 ,4 and 6 weeks
Study: NCT06715605

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tolerogenic dendritic cells (tolDC)
Description: In brief, clinical-grade tolDC vaccines will be prepared from leukapheresis starting material of non-mobilized blood and subsequent immunomagnetic selection of CD14+ monocytes using a CliniMACS device. CD14+ monocytes will then be cultured in GMP-grade cell culture medium supplemented with 2% human AB serum, GM-CSF, IL-4 and 1 alpha,25 dihydroxyvitamin D3. At day 4, tolDC will be stimulated using a cytokine cocktail to induce a migratory phenotype. At day 6, tolDC will be harvested, loaded with antigen, resuspended, and cryopreserved. Separate aliquots of the cell product are prepared for final quality control and quality assurance (QC/QA) assessment. This includes cell count, viability, phenotypic analysis using flow cytometry, and induction of T cell hyporesponsiveness in allo-MLR.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Standard-of-care on first-line treatment such as interferon-beta, glatiramer acetate, teriflunomide, dimethylfumarate, ponesimod and ozanimod.
Study: NCT05811975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSX01-TCRT injection
Description: individualization TCR-T cell injection
Study: NCT04996498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile bacteriostatic water ampule
Description: a placebo drug similar in shape to oxytocin ampules
Study: NCT05643144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: CGM education and glucose data collection for 14 days with a device. Interviews with dyads to assess experience and awareness of hypoglycemic events.
Study: NCT05001542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational moral injury video
Description: Educational video that addresses the identification of moral injury and distress in frontline healthcare workers during COVID-19; offers available interventions at the levels of individual, team and organization
Study: NCT06030622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)
Description: Combination treatment of Metformin, Simvastatin and Digoxin with Gemcitabine (Arm 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C3 (Metformin, Simvastatin, and Digoxin) only
Description: C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).
Study: NCT04868045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyrotropin Releasing Hormone (TRH)
Description: TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyrotropin Releasing Hormone (TRH)
Description: TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Description: Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine
Description: Patients maintenance dose of levothyroxine will be taken throughout the study. On Day~1 and Day 5, the levothyroxine will be taken after the TRH test is complete. On Days 2- 4, the levothyroxine will be taken in the morning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothyroidism QOL questionnaire
Description: Administer standardized Hypothyroidism QOL questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothyroidism QOL questionnaire
Description: Administer standardized Hypothyroidism QOL questionnaire.
Study: NCT06731270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given atezolizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given cemiplimab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04461964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine-vision Image Guided Surgery (MvIGS) spine navigation system.
Description: The intended use of the MvIGS navigation system is to provide high quality intraoperative imaging with no radiation exposure. Use of the proprietary integrated surgical light with embedded tracking technology and Flash™ registration allows for continuous and direct visualization of the surgical field. The MvIGS system is exempt from IDE regulations as the device cleared Premarket Notification FDA-510(k) (K162375). The device includes:~* A single mobile cart with a boom arm and an integrated surgical light with embedded tracking technology (P/N 10-0001);~* Proprietary imaging software (P/N 60-0007); and,~* Kit of tacked surgical instruments including a spine reference clamp, awl tip, pedicle probe (P/N 11-0006).
Study: NCT04965935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG Oral Tablet
Description: Dapagliflozin will be administered in a dose of 10 mg/day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching Dapagliflozin Oral Tablet
Description: Placebo will be administered for 12 weeks.
Study: NCT05001412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab; apatinib; carboplatin; etoposide
Description: 2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab; apatinib; carboplatin; etoposide
Description: 2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
Study: NCT05691062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium Fusion Device
Description: Titanium fusion device will be utilized for one-level lumbar fusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK Fusion Device
Description: PEEK fusion device will be utilized for one-level lumbar fusion.
Study: NCT05978362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet technique
Description: Realization of a stop according to Latarjet

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latarjet technique
Description: Realization of a stop according to Latarjet
Study: NCT05396118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of hyperpolarized [1-13C]Pyruvate
Description: Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MR/MRS/MRSI scanning
Description: Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.
Study: NCT06070051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC6
Description: VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC6
Description: VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC6
Description: VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC6
Description: VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC6
Description: VRON-0200 chimpanzee adenovirus serotype 6 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC7
Description: VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC7
Description: VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC7
Description: VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRON-0200-AdC7
Description: VRON-0200 chimpanzee adenovirus serotype 7 vaccine vector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection
Study: NCT06731270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given pembrolizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT05108636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic touch; It is a low-cost, non-contra-indications, easy-to-apply and non-invasive form of complementary therapy that can be applied anywhere and at any time (Vanaki et al., 2016). Therapeutic touch was developed by Krieger in 1975 as a nursing intervention to help and even heal the patient by balancing the patient's energy field (Marta et al., 2010). The basic assumption of therapeutic touch is that people have energy fields and these energy fields interact with the environment (Hanley, 2008). Therapeutic touch aims to harmonize, renew and heal the flow of the human energy field by removing the blockages of a person's biofield (Mueller et al., 2019). Unlike other touch-based methods such as massage therapy, therapeutic touch does not require the practitioner to physically touch the patient. Instead, the practitioner uses their hands to focus their energy and intent to help the recipient (Hanley, 2008).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Rest
Description: The use of music in the treatment of diseases has been seen in many civilizations since ancient times. In ancient Greek and Roman communities, individuals resorted to music to get rid of their humanitarian problems, while in Ancient Egypt, music was used to give strength to patients during birth (Kor \& Adar, 2016). In today's studies, it has been determined that music positively affects the physiological parameters, nutrition, hospital stay and sleep of the patients (O'Toole et al., 2017; Van Der Heijden et al., 2016). It is important that the sound level is within the appropriate limits while listening to music to the patients. The American Academy of Pediatrics recommends a sound level between 45dB- a maximum of 65dB (ACOG - AAP, 2012). The World Health Organization recommends a sound level of 35 dB during the day and 30 dB at night (Berglund et al., 2000).
Study: NCT06719128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olomorasib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olomorasib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olomorasib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olomorasib
Description: Administered orally.
Study: NCT05401019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Oral medication, once a day during 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral medication, once a day during 16 weeks